Małgorzata Całbecka

1.2k total citations
14 papers, 376 citations indexed

About

Małgorzata Całbecka is a scholar working on Genetics, Pathology and Forensic Medicine and Rheumatology. According to data from OpenAlex, Małgorzata Całbecka has authored 14 papers receiving a total of 376 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 5 papers in Rheumatology. Recurrent topics in Małgorzata Całbecka's work include Chronic Lymphocytic Leukemia Research (9 papers), Eosinophilic Disorders and Syndromes (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Małgorzata Całbecka is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Eosinophilic Disorders and Syndromes (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Małgorzata Całbecka collaborates with scholars based in Poland, Germany and Italy. Małgorzata Całbecka's co-authors include Lidia B. Brydak, Tadeusz Robak, Joanna Góra‐Tybor, Beata Stella‐Hołowiecka, Krzysztof Jamroziak, L Konopka, Anna Dmoszyńska, B. Ceglarek, Andrzej Hellmann and Grzegorz Helbig and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Małgorzata Całbecka

14 papers receiving 371 citations

Peers

Małgorzata Całbecka

GENET

PFM

HEMAT

RHEUM

IMMUN

D. Macdonald United Kingdom

M. Hoffknecht Germany

Kara Heelan United Kingdom

Marcella Arras Italy

Anna Maria Frustaci Italy

Gradimir Janković Serbia

Cristina Campidelli Italy

J. Eugene Huffstutter United States

A. Lakhani United Kingdom

Caroline Thomas France

D. Macdonald United Kingdom

Małgorzata Całbecka

137 ×0.6

GENET

66 ×0.5

PFM

202 ×1.8

HEMAT

138 ×1.3

RHEUM

134 ×1.4

IMMUN

Citations per year, relative to Małgorzata Całbecka Małgorzata Całbecka (= 1×) peers D. Macdonald

Countries citing papers authored by Małgorzata Całbecka

Since Specialization

Citations

This map shows the geographic impact of Małgorzata Całbecka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Małgorzata Całbecka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Małgorzata Całbecka more than expected).

Fields of papers citing papers by Małgorzata Całbecka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Małgorzata Całbecka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Małgorzata Całbecka. The network helps show where Małgorzata Całbecka may publish in the future.

Co-authorship network of co-authors of Małgorzata Całbecka

This figure shows the co-authorship network connecting the top 25 collaborators of Małgorzata Całbecka. A scholar is included among the top collaborators of Małgorzata Całbecka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Małgorzata Całbecka. Małgorzata Całbecka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Canzian, Federico, Joanna Góra‐Tybor, Daniele Campa, et al.. (2022). Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia. Frontiers in Oncology. 12. 952640–952640. 3 indexed citations

Góra‐Tybor, Joanna, et al.. (2015). Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leukemia & lymphoma. 56(8). 2309–2314. 36 indexed citations

Góra‐Tybor, Joanna, et al.. (2013). Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib. Blood. 122(21). 1491–1491. 3 indexed citations

Bąk, Aneta, M Kuliszkiewicz-Janus, Małgorzata Całbecka, et al.. (2011). A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations. Haematologica. 97(3). 366–370. 19 indexed citations

Robak, Tadeusz, Krzysztof Jamroziak, Joanna Góra‐Tybor, et al.. (2010). Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). Journal of Clinical Oncology. 28(11). 1863–1869. 71 indexed citations

Helbig, Grzegorz, Marek Hus, Jarosław Piszcz, et al.. (2009). Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1‐PDGFRA fusion transcript—results of Polish multicentre study. Hematological Oncology. 28(2). 93–97. 18 indexed citations

Jamroziak, Krzysztof, Olga Grzybowska‐Izydorczyk, Janusz Szemraj, et al.. (2009). CD38Gene Polymorphisms Contribute to Genetic Susceptibility to B-Cell Chronic Lymphocytic Leukemia: Evidence from Two Case-Control Studies in Polish Caucasians. Cancer Epidemiology Biomarkers & Prevention. 18(3). 945–953. 25 indexed citations

Helbig, Grzegorz, Beata Stella‐Hołowiecka, Mirosław Majewski, et al.. (2008). A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1‐PDGFRA‐expressing patients. British Journal of Haematology. 141(2). 200–204. 59 indexed citations

Zaucha, Jan Maciej, et al.. (2006). Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. Clinical & Laboratory Haematology. 28(3). 208–210. 4 indexed citations

10.

Robak, Tadeusz, Jerzy Z. Błoński, Joanna Góra‐Tybor, et al.. (2004). Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.. Blood. 104(11). 337–337. 8 indexed citations

11.

Robak, Tadeusz, Marek Kasznicki, Joanna Góra‐Tybor, et al.. (2004). Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.. Blood. 104(11). 3478–3478. 5 indexed citations

12.

Robak, Tadeusz, Jerzy Z. Błoński, Joanna Góra‐Tybor, et al.. (2003). Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. European Journal of Cancer. 40(3). 383–389. 55 indexed citations

13.

Robak, Tadeusz, Marek Kasznicki, Joanna Góra‐Tybor, et al.. (2001). Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia. 15(10). 1510–1516. 32 indexed citations

14.

Brydak, Lidia B. & Małgorzata Całbecka. (1999). Immunogenicity of Influenza Vaccine in Patients with Hemato-Oncological Disorders. Leukemia & lymphoma. 32(3-4). 369–374. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact